Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb 8;123(5):551-65.
doi: 10.1161/CIRCULATIONAHA.109.912568.

Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction

Thomas J Wang  1
Affiliations
Review

Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction

Thomas J Wang. Circulation. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression from risk factors to overt cardiovascular disease, showing the stages at which circulating, genetic, and imaging biomarkers are most informative.
Figure 2
Figure 2
Increment in discrimination from adding hypothetical biomarkers, according to the degree of marker-marker correlation (r). The simulated hazards ratio for the outcome is 1.35 per SD increment in the biomarker. The y-axis shows the c-statistic from a model containing traditional risk factors plus a variable number of simulated biomarkers (x-axis), each with a fixed association with the outcome. The simulation was performed by Michael Pencina, Boston University.
Figure 3
Figure 3
Figure 3A and 3B: Study designs for evaluating biomarker-guided treatment strategies, indirect approach (testing interaction of biomarker level and treatment, Figure 3A) and direct approach (randomization to biomarker or no biomarker measurement, Figure 3B). Modified, with permission, from Sargent.
Figure 3
Figure 3
Figure 3A and 3B: Study designs for evaluating biomarker-guided treatment strategies, indirect approach (testing interaction of biomarker level and treatment, Figure 3A) and direct approach (randomization to biomarker or no biomarker measurement, Figure 3B). Modified, with permission, from Sargent.
See this image and copyright information in PMC

References

    1. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904. - PubMed
    1. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:474–482. - PubMed
    1. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335–2362. - PubMed
    1. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, Humphrey LL. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:496–507. - PubMed
    1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes JI. Factors of risk in the development of coronary heart disease-- six year follow-up experience; the Framingham Study. Ann Intern Med. 1961;55:33–50. - PubMed

Publication types